Compare KRNT & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRNT | ENGN |
|---|---|---|
| Founded | 2002 | 1999 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.1M | 605.5M |
| IPO Year | 2015 | N/A |
| Metric | KRNT | ENGN |
|---|---|---|
| Price | $13.86 | $11.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $19.75 | ★ $22.71 |
| AVG Volume (30 Days) | 290.8K | ★ 328.0K |
| Earning Date | 02-11-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $210,041,000.00 | N/A |
| Revenue This Year | $3.86 | N/A |
| Revenue Next Year | $2.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.17 | N/A |
| 52 Week Low | $11.93 | $2.65 |
| 52 Week High | $31.24 | $11.14 |
| Indicator | KRNT | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.92 | 73.19 |
| Support Level | $13.64 | $8.68 |
| Resistance Level | $14.65 | $9.20 |
| Average True Range (ATR) | 0.51 | 0.74 |
| MACD | -0.12 | 0.21 |
| Stochastic Oscillator | 9.73 | 97.54 |
Kornit Digital Ltd develops, designs and markets digital printing solutions for the world-wide printed textile industry. The company focuses on its DTG and DTF segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software and value-added services that allow for large-scale printing of short runs of complex images and designs directly on finished garments and fabrics. It generates revenue from sales of systems, ink and other consumables and service including software subscriptions The company geographically operates in U.S., EMEA, Asia Pacific and other countries. It derives maximum revenue from U.S.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.